ArticleFrontiers in immunology2026

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study.

Xin Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.